2020
DOI: 10.3389/fmed.2020.00124
|View full text |Cite
|
Sign up to set email alerts
|

Hi-JAKi-ng Synovial Fibroblasts in Inflammatory Arthritis With JAK Inhibitors

Abstract: The Janus kinase (JAK)-Signal transducer and activator of transcription (STAT) pathway is one of the central signaling hubs in inflammatory, immune and cancer cells. Inhibiting the JAK-STAT pathway with JAK inhibitors (jakinibs) constitutes an important therapeutic strategy in cancer and chronic inflammatory diseases like rheumatoid arthritis (RA). FDA has approved different jakinibs for the treatment of RA, including tofacitinib, baricitinib and upadacitinib, and several jakinibs are being tested in clinical … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
18
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
8
1

Relationship

2
7

Authors

Journals

citations
Cited by 19 publications
(18 citation statements)
references
References 83 publications
(107 reference statements)
0
18
0
Order By: Relevance
“…All three types of interferons signal via the JAK-STAT signalling pathway, which, along with TNF, is one of the central therapeutic targets in RA. IFN pathways are strongly associated with the pathogenesis of RA and IFN-responsive genes are induced in FLS upon stimulation with TNF [ 45 ]. A type I interferon gene signature is detectable in up to two thirds of patients with RA [ 46 ], and it associates with an increased risk of developing RA as well as with therapeutic response to biological DMARDs like TNF inhibitors [ 47 , 48 ].…”
Section: Discussionmentioning
confidence: 99%
“…All three types of interferons signal via the JAK-STAT signalling pathway, which, along with TNF, is one of the central therapeutic targets in RA. IFN pathways are strongly associated with the pathogenesis of RA and IFN-responsive genes are induced in FLS upon stimulation with TNF [ 45 ]. A type I interferon gene signature is detectable in up to two thirds of patients with RA [ 46 ], and it associates with an increased risk of developing RA as well as with therapeutic response to biological DMARDs like TNF inhibitors [ 47 , 48 ].…”
Section: Discussionmentioning
confidence: 99%
“…[ 13 ] In addition, FDA‐approved Janus kinase inhibitors, such as tofacitinib, baricitinib and upadacitinib, can alleviate arthritis by interfering with the migration and invasion of FLS. [ 14 ] The biological anti‐rheumatic drug abatacept inhibits the migration and matrix metalloproteinase expression of FLS by preventing the activation of mitogen‐activated protein kinase signals and thereby delaying the development of RA. [ 15 ] The inhibition of FLS migration and invasion is the mechanism underlying the therapeutic effect of iguratimod, a new anti‐rheumatic drug approved in China and Japan.…”
Section: Introductionmentioning
confidence: 99%
“…IFN pathways are strongly associated with the pathogenesis of RA and IFN-responsive genes are induced in FLS upon stimulation with TNF 27 . The TNFAIP3/IFNGR1 region on chromosome 6 and the IFNAR1/IFNGR2 region on chromosome 21 interacted with genes encoding five subunits of the IFN I/III receptors in FLS (Fig.…”
Section: Resultsmentioning
confidence: 99%